Optimizing Therapy for Ovarian Cancer: Recent Data Highlights

Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.

Shannon N. Westin, MD, MPH, FACOG, explains the study design and outcomes of the SOLO-3 trial.

Bradley J. Monk, MD, FACOG, FACS, generates a discussion on the use of PARP inhibitors in ovarian cancer treatment.

Dr Michael Birrer reviews data from the PAOLA-1 trial investigating bevacizumab combination therapy for frontline maintenance therapy in advanced ovarian cancer.

Robert L. Coleman, MD, FACOG, FACS, describes data updates from the PRIMA trial investigating PARP inhibition in HRD-negative ovarian cancer populations.

Michael J. Birrer, MD, PhD, explains the reasoning for combining PARP inhibitors with immunotherapy in ovarian cancer treatment, highlighting ongoing trials.

A look at the maintenance treatment strategies for advanced or metastatic ovarian cancer.

Experts discuss the best approach to treating patients with ovarian cancer who are resistant to PARP inhibitors.

Dr Shannon Westin shares if and when she could justify withholding a PARP inhibitor from a patient with HRD-positive ovarian cancer.

Dr Michael Birrer highlights updated data on antibody-drug conjugates in ovarian cancer treatment.

Drs Coleman and Westin continue the discussion of antibody-drug conjugates for treatment of ovarian cancer.

A key opinion leader reviews data on novel investigational agents for recurrent ovarian cancer.

Dr Shannon Westin explains the data on treatment of rare tumors in ovarian cancer and why biomarker testing is essential.

The panel closes their discussion by highlighting their favorite news or update from recent conferences, including ESMO 2022.